Longitudinal variation of serum periostin levels in adults with stable asthma

Abstract

Braithwaite have all received grants from Genentech. C. Holweg is an employee of Genentech, a member of the Roche group. J. Matthews is employed by Genentech, a member of the Roche group, and is a named inventor on a pending patent application assigned to his employer relating to subject matter in the manuscript. R. Beasley reports grants from Genentech during the conduct of the study and personal fees from the Health Research Council of New Zealand, GlaxoSmithKline, AstraZeneca, and Novartis and grants from AstraZeneca, Chiesi, Cephalon, Genentech, Novartis, Sanofi Aventis, outside the submitted work. M. Weatherall declares that he has no conflicts of interest.

Advances in asthma in 2017: Mechanisms, biologics, and genetics

“…Another group looked at fluctuations in periostin levels in adults and found no evidence of fluctuation in serum levels over an 8-week period, suggesting levels in adults are stable. 70 Furthermore, the authors found no evidence of a seasonal effect on periostin levels. Together, these studies support the use of serum periostin as a biomarker for type 2-high asthma in adults and children.…”

The Clinical Relevance of Periostin in Asthma

“…The concept that the presence of high periostin levels may identify patients who are likely to respond to monoclonal antibody treatment directed against type-2 inflammation 4 was confirmed by a randomised controlled trial (RCT) of lebrikizumab (anti-IL-13 therapy) in adults with moderate-to-severe asthma and uncontrolled symptoms despite ICS therapy 14 . The "periostin-high" patients (those with a periostin level ≥ 50 ng/ml, the median observed in the patient cohort being analysed) had a greater improvement in FEV 1 in the lebrikizumab treatment arm compared to placebo whereas the "periostin-low" patients did not (Fig.…”

“…1b) 12 . In studies of predominantly Caucasian adults with asthma using the Elecsys ® Periostin immunoassay the median (IQR) periostin levels were between 47.7 (40.2 to 56.3) ng/ml and 54 (46 to 62) ng/ml (Table 1) [13][14][15]17,38,43,44,49,[54][55][56][57] . This is similar to a predominant Caucasian non-asthma population in which the median (IQR) level of 50.1 (43.1 to 56.9) ng/ml has been derived 38 .…”

“…It may also identify those with eosinophilic airway inflammation and those with eosinophilic infiltration of the lung parenchyma and sputum eosinophilia 5 . Periostin gene expression is reduced with ICS therapy 4 , and serum periostin levels are reduced with inhaled 13 and systemic 14 glucocorticoid treatment. High serum periostin levels may also indicate responsiveness to monoclonal antibody therapies targeting the type-2 inflammatory pathway, including IL-13 12,15,16 and IgE 17 .…”

“…Individual patient mean periostin levels ± 1 SD ranked by mean periostin level measured on eleven occasions over eight weeks (reproduced from Semprini R et al14 with permission from Elsevier).SD: standard deviation.BARCELONA RESPIRATORY NETWORKIgE, where seasonal variation does occur, attributed to variations in allergen exposures68,69 .…”